Psoriatic Arthritis News

Patients with psoriasis or psoriatic arthritis who are newly treated with IL-12/23 blockers demonstrated a reduced risk for serious infection compared with those who received TNF or IL-17 inhibitors, according to data published in Annals of the Rheumatic Diseases.

The FDA has approved the fourth biosimilar to infliximab, infliximab-axxq, for all eligible indications of the biologic product.

When journalist Ben Hammersley coined the word “podcast” in 2004, he was attempting to put a name to the phenomenon resulting from the timely convergence of widely available MP3 player technology, inexpensive audio software and weblog culture — a renaissance of radio programs that could be downloaded and played at the listener’s convenience, anytime or anywhere.

Among a large cohort of patients with psoriasis, researchers found around 20% had an immune-mediated inflammatory disease develop before psoriasis onset and 14% had one develop after psoriasis onset, according to a study using data from the Danish National Patient Registry.

ATLANTA — Lax FDA policies on required pediatric studies for approved biologic DMARDs have exacerbated an already critical lack of approved therapies for juvenile idiopathic arthritis and related conditions, according to a presentation at the 2019 ACR/ARP Annual Meeting.

In the dermatology setting, researchers found a substantial delay from symptom onset to a psoriatic arthritis diagnosis compared with rheumatology, according to LOOP, a multicenter study across 44 sites in the U.S.

ATLANTA — The use of either non-TNF inhibitor biologics or tofacitinib for chronic inflammatory diseases during pregnancy did not significantly increase risk for serious infections among infants, according to findings presented at the 2019 ACR/ARP Annual Meeting.

ATLANTA — A vast majority of patients with a cross-section of rheumatic diseases reported that pain, fatigue and mental health issues were those they would like researchers to track, according to a speaker at ACR/ARP 2019.

The FDA has approved Abrilada, a biosimilar to Humira, making it the fifth biosimilar to the reference drug and 25th biosimilar overall to gain approval in the United States, according to an agency press release.

Patients with psoriatic arthritis who also have depression were more likely to be on medications for PsA, had fewer swollen joints and lower disease activity via body surface area but also reported higher RAPID3 scores, according to research presented at the American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting.